Since the State Food and Drug Administration approved the import registration of Pfizer covid-19 virus therapeutic drug paxlovid with emergency conditions on February 11, the discussion on “who will eventually spend the Chinese agency right of Pfizer covid-19 therapeutic drug” has intensified. On March 10, China Meheco Group Co.Ltd(600056) trading limit opened. On the news side, China Meheco Group Co.Ltd(600056) won the commercial operation right of Pfizer covid-19 therapeutic drug in the Chinese market. The specific content of commercial operation and drug pricing are the focus of market concern. Some analysts speculate that China Meheco Group Co.Ltd(600056) is a listed company controlled by general technology group. As a listed pharmaceutical company under the national team of central enterprises, the cooperation with multinational well-known pharmaceutical enterprises this time includes not only commercial distribution, but also the coverage of a series of industrial chains such as overall commercial promotion and operation or later imitation. In the view of insiders, although the cooperation content is unknown, covid-19 oral medicine will be further commercialized and listed in China with the finalization of partners.
Partner
Pfizer covid-19 oral drug ushered in new progress. According to the announcement jointly issued by Pfizer and general technology China Meheco Group Co.Ltd(600056) , both parties signed an agreement on the combined packaging of nevitavir tablets / ritonavir tablets for covid-19 virus treatment. General technology China Meheco Group Co.Ltd(600056) will be responsible for the Pfizer Inc’s COVID-19 virus treatment business in the Chinese mainland market during the agreement period.
In February this year, the State Food and Drug Administration conducted emergency review and approval in accordance with the relevant provisions of the drug administration law and the special drug approval procedures, and conditionally approved the import registration of Pfizer’s covid-19 virus treatment drug nimatovir tablets / ritonavir tablets combined packaging (i.e. paxlovid).
Paxlovid is an oral small molecule COVID-19 virus therapy for the treatment of mild to moderate New Coronavirus pneumonia (COVID-19) in adults with severe risk factors, such as elderly, chronic kidney disease, diabetes, cardiovascular disease, and chronic lung disease.
Previously, there was a rumor in the market that general technology China Meheco Group Co.Ltd(600056) and a multinational pharmaceutical company were discussing the cooperation of covid-19 virus treatment drugs. Affected by this news, China Meheco Group Co.Ltd(600056) rose the limit for three consecutive trading days from March 2 to 4. The announcement revealed that the rumor was settled. On March 10, China Meheco Group Co.Ltd(600056) opened at the daily limit and closed up 10%.
For the specific contents of cooperation, the relevant person in charge of Pfizer told the Beijing Business Daily that “the contents of the announcement shall prevail”. As of press time, the relevant person in charge of General Technology Group has not replied.
cooperation details
The word “commercial operation” leaves room for imagination in the market. According to the announcement, the agreement period between China Meheco Group Co.Ltd(600056) and Pfizer is 2022. Pricing strategy, commercialization or commercial distribution are the focus of the market.
It is understood that as a listed company controlled by general technology group, China Meheco Group Co.Ltd(600056) is fully known as ” China Meheco Group Co.Ltd(600056) “. Its predecessor is China Meheco Group Co.Ltd(600056) health products import and Export Corporation established in 1984. It joined General Technology Group in 1999 and now becomes the only pharmaceutical and medical device asset integration platform of the group. From 2018 to 2020, China Meheco Group Co.Ltd(600056) achieved revenue of 31.006 billion yuan, 35.285 billion yuan and 39.312 billion yuan respectively; The net profit attributable to the parent company was 1.545 billion yuan, 981 million yuan and 1.311 billion yuan respectively. General technology group is an important state-owned backbone enterprise directly managed by the central government.
This time, Pfizer may not only lead a series of commercial enterprises to promote the overall distribution chain, but also lead a series of commercial enterprises such as Pfizer.
In November 2021, Pfizer announced that it had signed a sublicense agreement with the United Nations supported MPP (drug patent pool), which would allow more pharmaceutical companies to produce generic drugs of the company’s protease inhibitor pf-07321332 for low – and middle-income countries. According to the agreement reached between Pfizer and MPP, under the premise that who still defines covid-19 pneumonia as a public health crisis, MPP will be allowed to authorize the production of generic drugs to qualified pharmaceutical manufacturers without patent fee, and supply 95 low-income countries with ritonavir, covering 53% of the world’s population.
accelerated commercialization
With the finalization of partners, the commercialization of covid-19 oral medicine has accelerated Southwest Securities Co.Ltd(600369) it is estimated that the global oral covid-19 drug market will be billions to tens of billions of dollars, equivalent to nearly 100 billion yuan.
Pfizer is also preparing for capacity and supply. Pfizer previously disclosed that it would continue to increase investment in the production and distribution of paxlovid, and is expected to provide 120 million courses of drugs by the end of 2022.
Up to now, paxlovid has been approved for listing or authorized for emergency use in the United States, the United Kingdom, Israel, Canada and other countries / regions around the world. According to public information, Pfizer paxlovid is priced in the United States as a five-day course of treatment, and the U.S. government needs to pay about 530 dollars (about 3367 yuan). At present, the market speculates that the price in China may be 2000 yuan a course of treatment.
However, according to Li Xu, an investor in the pharmaceutical industry, emergency use means that it can only be used in designated hospitals. At present, the term of the agreement between China Meheco Group Co.Ltd(600056) and Pfizer is one year, which has a limited impact on China Meheco Group Co.Ltd(600056) ‘s performance China Meheco Group Co.Ltd(600056) also said in the announcement that the final use and sales of products are greatly uncertain due to factors such as epidemic prevention and control, and it is expected that the relevant business scale accounts for a small proportion of the company’s overall business volume, which has no significant impact on the company’s recent operating performance.
